CAR T stocks fall on solid tumor data

CAR T data from Novartis AG (NYSE:NVS; SIX:NOVN) and the University of Pennsylvania demonstrated much of what's already known about the challenges of moving the technology into the solid tumor setting. A presentation at the American Association for Cancer Research meeting in Philadelphia on Sunday showed no complete or partial responders among five patients receiving CART-meso.

The product is an intravenous infusion of autologous T cells transduced to express a CAR directed against mesothelin in patients with recurrent, advanced mesothelin-expressing solid tumors. ...